Targeting the hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cells

  title={Targeting the hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cells},
  author={Fernanda Fai{\~a}o-Flores and D{\'e}bora Kristina Alves-Fernandes and Paula Comune Pennacchi and Silvana Sandri and Anna Luiza Silva Almeida Vicente and Cristovam Scapulatempo-Neto and Vinicius de Lima Vazquez and Rui Manuel Reis and Jagat Singh Chauhan and Colin Ronald Goding and Keiran S. M. Smalley and Silvia Stuchi Maria-Engler},
  pages={1849 - 1861}
BRAF inhibitor (BRAFi) therapy for melanoma patients harboring the V600E mutation is initially highly effective, but almost all patients relapse within a few months. Understanding the molecular mechanisms underpinning BRAFi-based therapy is therefore an important issue. Here we identified a previously unsuspected mechanism of BRAFi resistance driven by elevated Hedgehog (Hh) pathway activation that is observed in a cohort of melanoma patients after vemurafenib treatment. Specifically, we… 
Investigating the role of Hedgehog/GLI1 signaling in glioblastoma cell response to temozolomide
Resistance to chemotherapy substantially hinders successful glioblastoma (GBM) treatment, contributing to an almost 100% mortality rate. Resistance to the frontline chemotherapy, temozolomide (TMZ),
Critical role of glioma‐associated oncogene homolog 1 in maintaining invasive and mesenchymal‐like properties of melanoma cells
Results indicate that GLI1 is important for maintaining the invasive and mesenchymal‐like properties of melanoma cells independent of MITF, most likely by modulating a subset of EMT‐TF.
Attenuation of hedgehog/GLI signaling by NT1721 extends survival in pancreatic cancer
Favorable therapeutics properties, i.e. 10-fold lower IC50 values than clinically used hedgehog inhibitors, a 90% reduction in liver metastasis and significantly better survival times compared to the standard-of-care drug, gemcitabine, provide a rational for testing NT1721 in the clinic either as a single agent or possibly in combination with gem citabine or other therapeutic agents in PDAC patients overexpressing GLI1/2.
Loss of Spry1 reduces growth of BRAFV600-mutant cutaneous melanoma and improves response to targeted therapy
It is reported that Spry1 knockdown (Spry1KO) in three BRAFV600-mutant CM cell lines markedly induced cell cycle arrest and apoptosis, repressed cell proliferation in vitro, and impaired tumor growth in vivo.
Up-regulation of GLI1 in vincristine-resistant rhabdomyosarcoma and Ewing sarcoma
It is demonstrated that GLI1 up-regulation contributes to VCR resistance in RMS and EWS cell lines and suggested that targetingGLI1 may benefit patients with RMS or EWS by reducing multidrug resistance.
Oncogenic GLI1 and STAT1/3 activation drives immunosuppressive tryptophan/kynurenine metabolism via synergistic induction of IDO1 in skin cancer cells
The immunosuppressive IDO1-kynurenine pathway is identified as a novel pro-tumorigenic effector of oncogenic HH-IL6 and GLI-STAT cooperation and suggests simultaneous pharmacological targeting of the HH/GLI, JAK/STAT and IDO 1- kynurenines axis as rational combination therapy in skin cancers.
The Role of Smoothened-Dependent and -Independent Hedgehog Signaling Pathway in Tumorigenesis
This review describes the various SMO-dependent andSMO-independent routes of GLI regulation in the tumorigenesis of multiple cancers in order to provide a holistic view of the paradigms of hedgehog signaling networks involvingGLI regulation.


Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways
The data uncover an unsuspected role of HH-GLI signaling in melanocytes and melanomas, demonstrate a role for this pathway in RAS-induced tumors, suggest a general integration of the RAS/AKT and HH- GLI pathways, and open a therapeutic approach for human melanomas.
Hedgehog–GLI Signaling Inhibition Suppresses Tumor Growth in Squamous Lung Cancer
An important role for GLI2 in LSCC is demonstrated, and GLI inhibition is suggested as a novel and potent strategy to treat a subset of patients with LSCC.
Targeting the Hedgehog signaling pathway in cancer: beyond Smoothened
GANT61 appears to be highly effective against human cancer cells and in xenograft mouse models, targeting almost all of the classical hallmarks of cancer and could hence represent a promising treatment option for human cancer.
A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors.
It is shown that RAF inhibitor-sensitive and inhibitor-resistant BRAF(V600)-mutant melanomas display distinct transcriptional profiles, which may modulate intrinsic sensitivity of melanomas to MAPK pathway inhibitors.
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
The findings provide a rationale for why some BRAF or MEK inhibitor-resistant melanoma patients may regain sensitivity to these drugs after a ‘drug holiday’ and identify patients with EGFR-positive melanoma as a group that may benefit from re-treatment after a drug holiday.
Aberrant GLI1 Activation in DNA Damage Response, Carcinogenesis and Chemoresistance
Current understanding of the molecular, biochemical and cellular basis for aberrant GLI1 expression is summarized andGLI1-mediated HH signaling on DNA damage responses, carcinogenesis and chemoresistance is discussed.
Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists
Two compounds are discovered that efficiently inhibited in vitro tumor cell proliferation in a GLI-dependent manner and successfully blocked cell growth in an in vivo xenograft model using human prostate cancer cells harboring downstream activation of the Hh pathway.
GLI2-mediated melanoma invasion and metastasis.
GLI2 was directly involved in driving melanoma invasion and metastasis in this preclinical study and was identified as a transcriptional target of TGF-beta signaling.